Welcome to our dedicated page for Adtalem Global Ed SEC filings (Ticker: ATGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Adtalem Global Education Inc. (NYSE: ATGE), a for-profit operator of colleges, universities, and professional schools with a strong emphasis on healthcare education. As a New York Stock Exchange–listed company, Adtalem files periodic and current reports that offer detailed information on its operations, financial condition, governance, and shareholder-related actions.
Annual reports on Form 10-K and quarterly reports on Form 10-Q contain segment-level data for the Chamberlain, Walden, and Medical and Veterinary segments, along with discussions of enrollment, revenue, operating income, and risk factors. These filings help readers understand how institutions such as Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine contribute to Adtalem’s overall results.
Current reports on Form 8-K document specific material events. Recent 8-K filings have covered the announcement of a new share repurchase authorization of up to $750 million and the completion of a prior $150 million repurchase program, the release of quarterly financial results, the retirement of the president of Chamberlain University, and the adoption of a Rule 10b5-1 trading plan by the company’s chief executive officer. Another 8-K reports the results of Adtalem’s annual meeting of shareholders, including director elections, auditor ratification, and an advisory vote on executive compensation.
Investors can also review Forms 4 and related insider trading disclosures referenced in company communications, which report transactions executed under trading plans such as the disclosed Rule 10b5-1 plan. Together, these filings provide a regulatory record of Adtalem’s financial performance, capital allocation decisions, governance matters, and insider activity.
Stock Titan’s platform enhances these filings with AI-powered summaries that highlight key points from lengthy documents, making it easier to identify segment performance, capital allocation actions, and governance changes without reading every page. Real-time updates from EDGAR ensure that new 10-K, 10-Q, 8-K, and Form 4 filings for ATGE are available promptly, while AI-generated explanations help readers interpret complex disclosures in accessible language.
Covista Inc. lead independent director Michael W. Malafronte reported open-market purchases of a total of 36,036 shares of Covista common stock. The trades were executed on March 10 and 11 at weighted average prices around $100.9 per share.
One purchase of 11,841 shares on March 10 was held directly, leaving 113,205 directly held shares after that trade. Two additional purchases of 15,305 and 8,890 shares were made for the Michael W Malafronte 2016 Gift Trust, an irrevocable trust for which he serves as trustee, bringing that trust’s reported holdings to 25,395 shares after the March 11 transaction.
Covista Inc. lead independent director Michael W. Malafronte reported that the Michael W Malafronte 2016 Gift Trust bought 1,200 shares of common stock in an open-market purchase at a weighted average price of $97.97 per share. The trust now holds 1,200 shares indirectly, while Malafronte directly holds 101,364 shares after the reported transactions.
Covista Inc. entered into an Amendment No. 5 to its Credit Agreement on March 2, 2026, creating new 2026 Term Loans with an aggregate original principal of $510 million maturing on March 2, 2033. These loans bear interest at Term SOFR plus 2.25% (with a 0.75% SOFR floor) or an alternate base rate plus 1.25%, and the amendment reduced term loan interest margins by 0.50%.
The company used the 2026 Term Loan proceeds to fully refinance existing term loans under the prior credit agreement and to redeem in full its 5.50% Senior Secured Notes due 2028. The redemption covered approximately $404,950,000 of principal at 100% of par plus accrued interest, after which the related indenture was fully satisfied and discharged.
Covista Inc. is using its Investor Day to lay out a new three-year growth strategy, called Purpose at Scale, focused on expanding its healthcare education platform and addressing the U.S. healthcare workforce shortage. The company now serves more than 97,000 students and has graduated 24,000 healthcare professionals in the last year, including 10% of America's nurses. Covista is reaffirming its fiscal 2026 outlook and introducing long-term targets for fiscal 2027–2029, aiming for annual revenue growth of 6–8%, 7–10% and 8–11%, and adjusted earnings per share growth of 9–13%, 10–14% and 12–16%, respectively. Management also highlights disciplined capital allocation, potential M&A and share repurchases, and notes that its stock will begin trading under the new ticker CVSA on the NYSE.
Ariel Investments, LLC reported beneficial ownership of 1,897,628 shares of Adtalem Global Education Inc common stock, representing 5.2% of the class as of 12/31/2025. Ariel has sole voting power over 1,671,303 shares and sole dispositive power over all 1,897,628 shares.
The shares are held for Ariel’s adviser clients, who are entitled to dividends and sale proceeds, but no single client has more than 5% of the outstanding stock. Ariel certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Adtalem.
Covista Inc., formerly Adtalem Global Education Inc., has officially changed its corporate name and updated its governing documents to reflect the new identity as of February 5, 2026. The company’s common stock will begin trading on the New York Stock Exchange under the ticker symbol CVSA on February 24, 2026, with existing stock certificates remaining valid.
The company is positioning itself as America’s largest healthcare educator, operating five accredited institutions that serve more than 97,000 students and a network of 385,000 alumni. Covista reports graduating about 24,000 healthcare professionals each year, including 10% of America’s nurses, and educating twice as many MDs as any MD-granting school in the U.S., as well as being the leading provider of Doctors of Veterinary Medicine to the U.S.
Covista also introduced the Covista Care Capacity Monitor, a research platform developed with Gallup to analyze healthcare workforce shortages across states and disciplines, and announced an Investor Day on February 24, 2026 to present its long-term strategic plan and investment priorities. In addition, Covista and The Covista Foundation launched the multi-year “Covista Open Doors” commitment to expand healthcare career pathways, support students through financial and mentoring programs, and address healthcare worker wellbeing.
Adtalem Global Education delivered higher results for the quarter ended December 31, 2025, with revenue of $503.4 million up from $447.7 million a year earlier and net income of $76.4 million versus $75.9 million.
Diluted earnings per share rose to $2.11 from $1.98, helped by strong contributions from Walden, where revenue increased to $217.6 million, and steady growth at the medical and veterinary schools. Six‑month revenue reached $965.7 million with net income of $138.2 million, both above the prior year.
Operating cash flow improved to $160.3 million for the first half, supporting significant capital returns and debt reduction. Long‑term debt fell to $504.3 million, while the company repurchased about 1.8 million shares for $172.5 million and launched a new $750 million buyback program with substantial remaining authorization.
Adtalem Global Education Inc. filed a current report to note it has released its second quarter fiscal 2026 academic, operating and financial results. The company states these results in a separate press release dated January 28, 2026, which is attached as an exhibit.
The filing also includes a standard caution that certain statements about future growth and other expectations are forward-looking and subject to risks and uncertainties, referring readers to the company’s most recent annual report and other SEC filings for detailed risk factors.
Dimensional Fund Advisors LP filed an updated ownership report on Adtalem Global Education Inc, showing beneficial ownership of 1,766,448 shares of common stock, or 4.9% of the class, as of December 31, 2025. Dimensional reports sole power to vote 1,708,304 shares and sole power to dispose of 1,766,448 shares, with no shared voting or dispositive power.
The shares are held across various funds and accounts it advises, and Dimensional disclaims beneficial ownership beyond what is required for Section 13(d) reporting. It also certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Adtalem.
Adtalem Global Education Inc. reported that its Board of Directors has authorized the repurchase of up to an additional $750 million of its common stock. The company may buy shares over time through open market purchases, accelerated share repurchases, privately negotiated deals or other methods, in line with Rule 10b-18 and subject to market conditions, through the period ending December 15, 2028.
Adtalem also announced that it has completed its prior share repurchase program, under which it repurchased $150 million of its shares. The company noted that the new authorization does not require it to repurchase a specific number of shares and can be suspended, modified or terminated at any time without prior notice.